Skip to main content
. 2021 Sep 2;11(5):1751–1762. doi: 10.1007/s13555-021-00594-w

Table 3.

Number of AK lesions—percentage change at T2 versus baseline

Kerà K2® (N = 30) Placebo (N = 26) Comparison between treatments Wilcoxon rank-sum test (p value)
Baseline
 Mean 5.53 4.96
 SD 2.40 2.75
Visit T2 (day 180)
 Mean 3.17 4.65
 SD 1.49 2.67
Visit T2—percentage change versus baseline
 Mean  −42.78  −6.20  < 0.001
 SD 26.53 31.57